Cargando…

Use of new recombinant proteins for ovarian stimulation in ruminants

Currently, gonadotropin products (follicle stimulating hormone, FSH, and luteinizing hormone, LH) used in animal reproduction are produced by extraction and purification from abattoir-derived pituitary glands. This method, relying on animal-derived materials, carries the potential risk of hormone co...

Descripción completa

Detalles Bibliográficos
Autores principales: Baruselli, Pietro Sampaio, de Abreu, Laís Ângelo, Catussi, Bruna Lima Chechin, Oliveira, Ana Carolina dos Santos, Rebeis, Lígia Mattos, Gricio, Emanuele Almeida, Albertini, Sofía, Sales, José Nélio Sousa, Rodrigues, Carlos Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Colégio Brasileiro de Reprodução Animal 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503889/
https://www.ncbi.nlm.nih.gov/pubmed/37720727
http://dx.doi.org/10.1590/1984-3143-AR2023-0092
_version_ 1785106617976487936
author Baruselli, Pietro Sampaio
de Abreu, Laís Ângelo
Catussi, Bruna Lima Chechin
Oliveira, Ana Carolina dos Santos
Rebeis, Lígia Mattos
Gricio, Emanuele Almeida
Albertini, Sofía
Sales, José Nélio Sousa
Rodrigues, Carlos Alberto
author_facet Baruselli, Pietro Sampaio
de Abreu, Laís Ângelo
Catussi, Bruna Lima Chechin
Oliveira, Ana Carolina dos Santos
Rebeis, Lígia Mattos
Gricio, Emanuele Almeida
Albertini, Sofía
Sales, José Nélio Sousa
Rodrigues, Carlos Alberto
author_sort Baruselli, Pietro Sampaio
collection PubMed
description Currently, gonadotropin products (follicle stimulating hormone, FSH, and luteinizing hormone, LH) used in animal reproduction are produced by extraction and purification from abattoir-derived pituitary glands. This method, relying on animal-derived materials, carries the potential risk of hormone contamination and pathogen transmission. Additionally, chorionic gonadotropins are extracted from the blood of pregnant mares (equine chorionic gonadotropin; eCG) or the urine of pregnant women (human chorionic gonadotropin; hCG). However, recent advancements have introduced recombinant gonadotropins for assisted animal reproduction therapies. The traditional use of FSH for superovulation has limitations, including labor requirements and variability in superovulation response, affecting the success of in vivo (SOV) and in vitro (OPU/IVEP) embryo production. FSH treatment for superstimulation before OPU can promote the growth of a homogenous follicular population and the recovery of competent oocytes suitable for IVEP procedures. At present, a single injection of a preparation of long-acting bovine recombinant FSH (rFSH) produced similar superovulation responses resulting in the production of good-quality in vivo and in vitro embryos. Furthermore, the treatment with eCG at FTAI protocol has demonstrated its efficacy in promoting follicular growth, ovulation, and P/AI, mainly in heifers and anestrous cows. Currently, treatment with recombinant glycoproteins with eCG-like activity (r-eCG) have shown promising results in increasing follicular growth, ovulation, and P/AI in cows submitted to P4/E2 -based protocols. Bovine somatotropin (bST) is a naturally occurring hormone found in cows. Recombinant bovine somatotropin (rbST), produced through genetic engineering techniques, has shown potential in enhancing reproductive outcomes in ruminants. Treatment with rbST has been found to improve P/IA, increase donor embryo production, and enhance P/ET in recipients. The use of recombinant hormones allows to produce non-animal-derived products, offering several advantages in assisted reproductive technologies for ruminants. This advancement opens up new possibilities for improving reproductive efficiency and success rates in the field of animal reproduction.
format Online
Article
Text
id pubmed-10503889
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Colégio Brasileiro de Reprodução Animal
record_format MEDLINE/PubMed
spelling pubmed-105038892023-09-16 Use of new recombinant proteins for ovarian stimulation in ruminants Baruselli, Pietro Sampaio de Abreu, Laís Ângelo Catussi, Bruna Lima Chechin Oliveira, Ana Carolina dos Santos Rebeis, Lígia Mattos Gricio, Emanuele Almeida Albertini, Sofía Sales, José Nélio Sousa Rodrigues, Carlos Alberto Anim Reprod Thematic Section: 36th Annual Meeting of the Brazilian Embryo Technology Society (SBTE) Currently, gonadotropin products (follicle stimulating hormone, FSH, and luteinizing hormone, LH) used in animal reproduction are produced by extraction and purification from abattoir-derived pituitary glands. This method, relying on animal-derived materials, carries the potential risk of hormone contamination and pathogen transmission. Additionally, chorionic gonadotropins are extracted from the blood of pregnant mares (equine chorionic gonadotropin; eCG) or the urine of pregnant women (human chorionic gonadotropin; hCG). However, recent advancements have introduced recombinant gonadotropins for assisted animal reproduction therapies. The traditional use of FSH for superovulation has limitations, including labor requirements and variability in superovulation response, affecting the success of in vivo (SOV) and in vitro (OPU/IVEP) embryo production. FSH treatment for superstimulation before OPU can promote the growth of a homogenous follicular population and the recovery of competent oocytes suitable for IVEP procedures. At present, a single injection of a preparation of long-acting bovine recombinant FSH (rFSH) produced similar superovulation responses resulting in the production of good-quality in vivo and in vitro embryos. Furthermore, the treatment with eCG at FTAI protocol has demonstrated its efficacy in promoting follicular growth, ovulation, and P/AI, mainly in heifers and anestrous cows. Currently, treatment with recombinant glycoproteins with eCG-like activity (r-eCG) have shown promising results in increasing follicular growth, ovulation, and P/AI in cows submitted to P4/E2 -based protocols. Bovine somatotropin (bST) is a naturally occurring hormone found in cows. Recombinant bovine somatotropin (rbST), produced through genetic engineering techniques, has shown potential in enhancing reproductive outcomes in ruminants. Treatment with rbST has been found to improve P/IA, increase donor embryo production, and enhance P/ET in recipients. The use of recombinant hormones allows to produce non-animal-derived products, offering several advantages in assisted reproductive technologies for ruminants. This advancement opens up new possibilities for improving reproductive efficiency and success rates in the field of animal reproduction. Colégio Brasileiro de Reprodução Animal 2023-09-04 /pmc/articles/PMC10503889/ /pubmed/37720727 http://dx.doi.org/10.1590/1984-3143-AR2023-0092 Text en https://creativecommons.org/licenses/by/4.0/Copyright © The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Thematic Section: 36th Annual Meeting of the Brazilian Embryo Technology Society (SBTE)
Baruselli, Pietro Sampaio
de Abreu, Laís Ângelo
Catussi, Bruna Lima Chechin
Oliveira, Ana Carolina dos Santos
Rebeis, Lígia Mattos
Gricio, Emanuele Almeida
Albertini, Sofía
Sales, José Nélio Sousa
Rodrigues, Carlos Alberto
Use of new recombinant proteins for ovarian stimulation in ruminants
title Use of new recombinant proteins for ovarian stimulation in ruminants
title_full Use of new recombinant proteins for ovarian stimulation in ruminants
title_fullStr Use of new recombinant proteins for ovarian stimulation in ruminants
title_full_unstemmed Use of new recombinant proteins for ovarian stimulation in ruminants
title_short Use of new recombinant proteins for ovarian stimulation in ruminants
title_sort use of new recombinant proteins for ovarian stimulation in ruminants
topic Thematic Section: 36th Annual Meeting of the Brazilian Embryo Technology Society (SBTE)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503889/
https://www.ncbi.nlm.nih.gov/pubmed/37720727
http://dx.doi.org/10.1590/1984-3143-AR2023-0092
work_keys_str_mv AT barusellipietrosampaio useofnewrecombinantproteinsforovarianstimulationinruminants
AT deabreulaisangelo useofnewrecombinantproteinsforovarianstimulationinruminants
AT catussibrunalimachechin useofnewrecombinantproteinsforovarianstimulationinruminants
AT oliveiraanacarolinadossantos useofnewrecombinantproteinsforovarianstimulationinruminants
AT rebeisligiamattos useofnewrecombinantproteinsforovarianstimulationinruminants
AT gricioemanuelealmeida useofnewrecombinantproteinsforovarianstimulationinruminants
AT albertinisofia useofnewrecombinantproteinsforovarianstimulationinruminants
AT salesjoseneliosousa useofnewrecombinantproteinsforovarianstimulationinruminants
AT rodriguescarlosalberto useofnewrecombinantproteinsforovarianstimulationinruminants